NASDAQ:CTXR Citius Pharmaceuticals - CTXR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.98 -0.04 (-3.94%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.96▼$1.0350-Day Range$0.92▼$1.4252-Week Range$0.77▼$2.01Volume675,985 shsAverage Volume882,003 shsMarket Capitalization$142.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Citius Pharmaceuticals (NASDAQ:CTXR) StockCitius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.Read More Receive CTXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CTXR Stock News HeadlinesMarch 18, 2023 | uk.finance.yahoo.comCitius Pharmaceuticals, Inc. (CTXR)March 8, 2023 | finance.yahoo.comCitius Pharmaceuticals to Participate in the 35th Annual Roth ConferenceMarch 21, 2023 | Investing Daily (Ad)This Trade Strategy Outpaces Almost AnythingDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. February 10, 2023 | finance.yahoo.comCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business UpdateFebruary 6, 2023 | finance.yahoo.comHere Are 2 Ways I'm Playing the Market With Small-Cap StocksJanuary 16, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn SituationJanuary 11, 2023 | finance.yahoo.comCitius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023December 28, 2022 | finance.yahoo.comAfter Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)March 21, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.December 22, 2022 | benzinga.comCitius Pharmaceuticals Reports $41.7M In Cash And Cash Equivalents As Of Sept. 30December 22, 2022 | finance.yahoo.comCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business UpdateDecember 1, 2022 | nasdaq.comCitius: FDA To Review BLA For Denileukin Diftitox - Quick FactsDecember 1, 2022 | finance.yahoo.comCitius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell LymphomaNovember 21, 2022 | finance.yahoo.comCitius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development ProgramNovember 9, 2022 | finance.yahoo.comCitius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual MeetingOctober 18, 2022 | finance.yahoo.comCitius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Profit OutlookOctober 18, 2022 | finance.yahoo.comCitius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022October 6, 2022 | finance.yahoo.comCitius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022September 28, 2022 | nasdaq.comCitius Pharma Announces BLA Filing For Denileukin Diftitox - Quick FactsSeptember 28, 2022 | marketwatch.comCitius Pharmaceuticals Seeks FDA OK of Reformulated Ontak Drug >CTXRSeptember 28, 2022 | finance.yahoo.comCitius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell LymphomaSeptember 23, 2022 | seekingalpha.comCitius gains on clinical collaboration to study cancer candidateSeptember 23, 2022 | finance.yahoo.comCitius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-Initiated TrialSeptember 10, 2022 | benzinga.comCitius Pharmaceuticals, Inc. to Present at the H....September 7, 2022 | finance.yahoo.comCitius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 11, 2022 | finance.yahoo.comCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business UpdateAugust 9, 2022 | finance.yahoo.comHere's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash WiselySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CTXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CTXR Company Calendar Last Earnings12/22/2022Today3/20/2023Next Earnings (Estimated)5/11/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTXR CUSIPN/A CIK1506251 Webwww.citiuspharma.com Phone(908) 967-6677FaxN/AEmployees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.19% Return on Assets-26.67% Debt Debt-to-Equity RatioN/A Current Ratio9.33 Quick Ratio9.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book1.37Miscellaneous Outstanding Shares146,260,000Free Float123,442,000Market Cap$142.72 million OptionableNot Optionable Beta1.40 Key ExecutivesLeonard L. MazurChairman, Chief Executive Officer & SecretaryGary F. TalaricoExecutive Vice President-OperationsJaime BartushakChief Financial & Business OfficerAlan LaderSVP, Head-Clinical Operations & Quality AssuranceMyron S. CzuczmanChief Medical Officer & Executive Vice PresidentKey CompetitorsOptiNoseNASDAQ:OPTNIncannex HealthcareNASDAQ:IXHLImmutepNASDAQ:IMMPVeruNASDAQ:VERULifecore BiomedicalNASDAQ:LFCRView All CompetitorsInstitutional OwnershipMillennium Management LLCSold 233,654 shares on 2/15/2023Ownership: 0.377%Morgan StanleySold 37,136 shares on 2/15/2023Ownership: 0.076%Man Group plcBought 33,716 shares on 2/15/2023Ownership: 0.032%Virtu Financial LLCBought 39,005 shares on 2/15/2023Ownership: 0.027%Susquehanna International Group LLPSold 600 shares on 2/14/2023Ownership: 0.000%View All Institutional Transactions CTXR Stock - Frequently Asked Questions How have CTXR shares performed in 2023? Citius Pharmaceuticals' stock was trading at $0.79 on January 1st, 2023. Since then, CTXR stock has increased by 23.5% and is now trading at $0.9758. View the best growth stocks for 2023 here. When is Citius Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our CTXR earnings forecast. How were Citius Pharmaceuticals' earnings last quarter? Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) posted its earnings results on Thursday, December, 22nd. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.01. When did Citius Pharmaceuticals' stock split? Shares of Citius Pharmaceuticals reverse split on the morning of Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 8th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Citius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), KushCo (KSHB) and Gran Tierra Energy (GTE). What is Citius Pharmaceuticals' stock symbol? Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR." Who are Citius Pharmaceuticals' major shareholders? Citius Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.91%), Millennium Management LLC (0.38%), GSA Capital Partners LLP (0.34%), Renaissance Technologies LLC (0.28%), HighTower Advisors LLC (0.13%) and Morgan Stanley (0.08%). View institutional ownership trends. How do I buy shares of Citius Pharmaceuticals? Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Citius Pharmaceuticals' stock price today? One share of CTXR stock can currently be purchased for approximately $0.98. How much money does Citius Pharmaceuticals make? Citius Pharmaceuticals (NASDAQ:CTXR) has a market capitalization of $142.72 million. The company earns $-33,640,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. How can I contact Citius Pharmaceuticals? Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The official website for the company is www.citiuspharma.com. The company can be reached via phone at (908) 967-6677 or via email at ir@citiuspharma.com. This page (NASDAQ:CTXR) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.